作者
Kirsten P Perrett, Scott A Halperin, Terry Nolan, Alfonso Carmona Martínez, Federico Martinón-Torres, Jose García-Sicilia, Miia Virta, Otto G Vanderkooi, Gian Vincenzo Zuccotti, Paolo Manzoni, Lusine Kostanyan, Nadia Meyer, Maria Angeles Ceregido, Brigitte Cheuvart, Sherine O Kuriyakose, Zbynek Stranak, Jose M Merino Arribas, María José Cilleruelo Ortega, Mariano Miranda-Valdivieso, Begoña Arias Novas, Jose Tomas Ramos Amador, Felix Omeñaca, Manuel Baca, Paola Giovanna Marchisio, Narcisa Mesaros
发表日期
2020/2/18
期刊
Vaccine
卷号
38
期号
8
页码范围
2105-2114
出版商
Elsevier
简介
Background
Pertussis immunization during pregnancy results in high pertussis antibody concentrations in young infants but may interfere with infant immune responses to post-natal immunization.
Methods
This phase IV, multi-country, open-label study assessed the immunogenicity and safety of infant primary vaccination with DTaP-HepB-IPV/Hib and 13-valent pneumococcal conjugate vaccine (PCV13). Enrolled infants (6–14 weeks old) were born to mothers who were randomized to receive reduced-antigen-content diphtheria-tetanus-three-component acellular pertussis vaccine (Tdap group) or placebo (control group) during pregnancy (270/7–366/7 weeks’ gestation) with crossover immunization postpartum. All infants received 2 or 3 DTaP-HepB-IPV/Hib and PCV13 doses according to national schedules. Immunogenicity was assessed in infants pre- and 1 month post-primary vaccination. The primary objective …
学术搜索中的文章
KP Perrett, SA Halperin, T Nolan, AC Martínez… - Vaccine, 2020